Target intelligence / Profile preview

DHRS4 antisense RNA 1 (DHRS4-AS1)

Target
DHRS4-AS1
Molecular classification
Long noncoding RNA (lncRNA), Natural antisense transcript (NAT)
01

Overview

DHRS4 antisense RNA 1 (DHRS4-AS1) is a long noncoding natural antisense transcript located head-to-head with the DHRS4 protein-coding gene. It regulates the DHRS4 gene cluster (including DHRS4, DHRS4L2, DHRS4L1) through epigenetic mechanisms such as histone deacetylation and methylation, and by recruiting chromatin modifiers (G9a, EZH2) and DNA methyltransferases. DHRS4-AS1 is implicated in cancer, notably acting as a tumor suppressor in osteosarcoma by suppressing cell proliferation and inducing apoptosis through a microRNA-dependent pathway (e.g., modulates the miR-362-5p/NPEPPS axis)[1][3][4]. Its regulatory functions extend to chromatin structure, gene silencing, and potentially other processes tied to its expression profile in normal and cancerous cells. If further nomenclature issues arise: The supplied abbreviation "ENSG00000308027" does not match standard ENSG (Ensembl Gene) identifiers—these typically have seven digits. It may be a typographical error or a database-specific reference; the molecule described here matches all known properties of DHRS4 antisense RNA 1 (DHRS4-AS1)[1][3][4].

Other names
AS1DHRS4natural antisense transcript to DHRS4DHRS4-AS1C14ORF167-associated antisense
02

Mechanism of action

Epigenetic silencing via chromatin modification (interaction with histone methyltransferases G9a and EZH2, leading to H3K9me2 and H3K27me3 modifications); DNA methylation by recruiting DNA methyltransferases; Competing endogenous RNA (ceRNA) mechanism: acts as a sponge for miR-362-5p and thus regulates aminopeptidase puromycin sensitive (NPEPPS)

03

Biological functions

Epigenetic regulation (silencing by histone modification)Transcriptional regulation of gene cluster (DHRS4 family)Regulation of cell proliferation and apoptosis in osteosarcomaMicroRNA sponge activity (modulates miR-362-5p)
04

Disease associations

Cancer (specifically osteosarcoma, and possibly other cancer types)Potential regulatory role in other diseases involving the DHRS4 gene cluster
05

Safety considerations

No notable safety concerns are reported; therapeutic targeting of lncRNAs generally faces delivery and specificity challenges
06

Biomarkers

DHRS4-AS1 expression levels may serve as a biomarker in osteosarcoma for prognosis and therapy stratification

Beyond the preview

Go deeper on DHRS4 antisense RNA 1 (DHRS4-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHRS4 antisense RNA 1 (DHRS4-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call